Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yang-Tze Broussard

Internal Medicine Lake Charles, LA Medical Doctor

NPI 1922099662 CMS profile 314409

1722 Westwood St, Lake Charles, LA 70601

Open in the dashboard

General payments

$6,745

225 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yang-Tze Broussard of Lake Charles, LA is reported in the CMS Open Payments database as having received $6,745 across 225 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $797 23
2024 General $635 24
2023 General $1,327 39
2022 General $918 30
2021 General $1,431 45
2020 General $596 24
2019 General $1,041 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yang-Tze Broussard
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Yang-Tze Broussard were reported at $797. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Yang-Tze Broussard Internal Medicine median Middle half National median
2019 $1,041 $159 $48–$570 $163
2020 $596 $119 $33–$402 $114
2021 $1,431 $135 $37–$521 $132
2022 $918 $141 $42–$496 $149
2023 $1,327 $149 $45–$519 $160
2024 $635 $154 $47–$537 $164
2025 $797 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,145 30 payments
  2. AbbVie, Inc. $825 30 payments
  3. Novo Nordisk Inc $639 19 payments
  4. Esperion Therapeutics, Inc. $487 6 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $393 8 payments
  6. Pfizer Inc. $371 26 payments
  7. Amgen Inc. $347 11 payments
  8. Corium, Inc. $258 9 payments
  9. ITI, Inc. $246 2 payments
  10. Lilly USA, LLC $233 15 payments
  11. Other $1,801 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,733 224 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $1,127 29 payments
  2. NEXLETOL $487 6 payments
  3. NEXLIZET $453 4 payments
  4. VRAYLAR $431 16 payments
  5. Ozempic $416 14 payments
  6. JARDIANCE $360 6 payments
  7. Repatha $347 11 payments
  8. EUCRISA $304 22 payments
  9. Azstarys $258 9 payments
  10. UBRELVY $253 11 payments
  11. Other $3,785 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 95 drugs

Part D claims

4,059

Median for Pediatric Medicine: 38

Drug cost

$345,834

Median for Pediatric Medicine: $2,769

Branded share of claims

20.8%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 70 $92,740
Mounjaro Tirzepatide Brand 37 $37,288
Eliquis Apixaban Brand 41 $32,469
Januvia Sitagliptin Phosphate Brand 36 $32,405
Farxiga Dapagliflozin Propanediol Brand 49 $30,730
Jardiance Empagliflozin Brand 17 $25,432
Trulicity Dulaglutide Brand 16 $19,343
Tresiba Flextouch U-200 Insulin Degludec Brand 20 $11,896
Entresto Sacubitril/Valsartan Brand 13 $9,207
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 11 $5,383

The 10 drugs with the highest cost, of 95 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 129 billing codes

Paid by Medicare

$177,046

Of which drugs: $22,779

Medicare patients

600

Average age 73

Services billed

12,274

347 women, 253 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 33%
Diabetes 32%
Chronic kidney disease 26%
Depression 23%
Atrial fibrillation 17%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 65 65 $5,318
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 33 33 $4,316
Pcv20 vaccine im 90677 Office 12 13 $3,751
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 152 641 $3,495
Vaccine for influenza for injection into muscle 90662 Office 37 37 $3,027
Injection, methylprednisolone acetate, 1 mg J1010 Office 23 4,140 $418
Injection, ceftriaxone sodium, per 250 mg J0696 Office 84 370 $126
Injection, methylprednisolone acetate, 80 mg J1040 Office 11 22 $62
Injection, ketorolac tromethamine, per 15 mg J1885 Office 13 48 $27

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $134
$134 49 —
NEXLETOL
  • Esperion Therapeutics, Inc. $69
$69 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $62
$62 — —
NEXLIZET
  • Esperion Therapeutics, Inc. $55
$55 — —
Repatha
  • Amgen Inc. $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record